Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor, Carfilzomib, Isatuximab, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT07479979Phase 2Recruiting
- Start
- May 2026
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of selinexor in multiple myeloma (MM) (2 arms). Primary endpoint: Adverse Events at 24 months. Started May 2026; status: recruiting.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07479979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07479979.